XARELTO®: Coronary artery disease (CAD) and peripheral artery disease (PAD) treatment

In the COMPASS trial, the XARELTO® vascular dose* significantly reduced a composite of CV death, MI, and stroke in patients with CAD and/or PAD.1

The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2

*Patients with coronary syndromes (CAD) and in sinus rhythm.

Not adjusted for multiplicity.

CAD = coronary artery disease; CV = cardiovascular; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; MI = myocardial infarction; PAD = peripheral artery disease.